Wells Fargo
SGMT icon

Wells Fargo’s Sagimet Biosciences SGMT Stock Holding History

Wells Fargo’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.5K Buy
9,274
+1,274
+16% +$7.1K ﹤0.01% 5465
2025
Q4 		$47.4K Buy
8,000
+1,000
+14% +$7.18K ﹤0.01% 5589
2025
Q3 		$48K Buy
7,000
+500
+8% +$4.05K ﹤0.01% 5559
2025
Q2 		$49.5K Sell
6,500
-11,000
-63% -$46.4K ﹤0.01% 5509
2025
Q1 		$57K Buy
17,500
+10,690
+157% +$44.8K ﹤0.01% 5356
2024
Q4 		$30.6K Buy
+6,810
New +$34.5K ﹤0.01% 5633
2024
Q2 		– Sell
-7,519
Closed -$40.8K – 7396
2024
Q1 		$40.8K Buy
7,519
+5,931
+373% +$42.6K ﹤0.01% 5340
2023
Q4 		$8.61K Buy
1,588
+373
+31% +$1.76K ﹤0.01% 5870
2023
Q3 		$10.7K Buy
+1,215
New +$16.2K ﹤0.01% 5792

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wells Fargo's SGMT Position: Q1 2026 in Review

Wells Fargo increased its Sagimet Biosciences (SGMT) stake by 16% in Q1 2026, buying an estimated $7.1K and bringing the position to 9,274 shares worth $48.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5465.

Wells Fargo first reported a position in SGMT in Q3 2023 and has held it in 9 quarters since. The position peaked at $57K in Q1 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Wells Fargo held 9,274 shares of Sagimet Biosciences worth $48.5K as of Q1 2026.
  • Wells Fargo bought 1,274 Sagimet Biosciences shares in Q1 2026, an estimated $7.1K.
  • Sagimet Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5465 holding.
  • Wells Fargo first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 9 quarters since.
  • Wells Fargo's Sagimet Biosciences position peaked at $57K in Q1 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.